[
  {
    "ts": "2026-01-06T04:26:57+00:00",
    "headline": "BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)",
    "summary": "BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovarian cancer. This early efficacy signal in a difficult-to-treat cancer adds another potential use case for KEYTRUDA, underscoring the importance of Merck’s immuno-oncology collaborations. Next, we’ll examine how this early ovarian cancer data for the...",
    "url": "https://finance.yahoo.com/news/bioinvent-keytruda-ovarian-cancer-signal-042657084.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "38f0988c-9083-3f1a-b675-cc4037bc12e6",
      "content": {
        "id": "38f0988c-9083-3f1a-b675-cc4037bc12e6",
        "contentType": "STORY",
        "title": "BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)",
        "description": "",
        "summary": "BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovarian cancer. This early efficacy signal in a difficult-to-treat cancer adds another potential use case for KEYTRUDA, underscoring the importance of Merck’s immuno-oncology collaborations. Next, we’ll examine how this early ovarian cancer data for the...",
        "pubDate": "2026-01-06T04:26:57Z",
        "displayTime": "2026-01-06T04:26:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bioinvent-keytruda-ovarian-cancer-signal-042657084.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bioinvent-keytruda-ovarian-cancer-signal-042657084.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BOVNF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T14:13:00+00:00",
    "headline": "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines",
    "summary": "The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The \"TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook",
    "url": "https://finance.yahoo.com/news/tigit-inhibitors-drugs-clinical-trials-141300202.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c06f4821-64a0-353e-9af8-ddceff8c3bc5",
      "content": {
        "id": "c06f4821-64a0-353e-9af8-ddceff8c3bc5",
        "contentType": "STORY",
        "title": "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines",
        "description": "",
        "summary": "The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The \"TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook",
        "pubDate": "2026-01-06T14:13:00Z",
        "displayTime": "2026-01-06T14:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tigit-inhibitors-drugs-clinical-trials-141300202.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tigit-inhibitors-drugs-clinical-trials-141300202.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RCUS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T14:00:06+00:00",
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-140006505.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c6993e08-9a8c-3fb0-aeb2-7f28513c83ee",
      "content": {
        "id": "c6993e08-9a8c-3fb0-aeb2-7f28513c83ee",
        "contentType": "STORY",
        "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
        "description": "",
        "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
        "pubDate": "2026-01-06T14:00:06Z",
        "displayTime": "2026-01-06T14:00:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4",
          "originalWidth": 900,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/96m3P4v2KypZ_.2vXHQRKA--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4.cf.webp",
              "width": 900,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TvxSS8VO1p90iNVKrfS9eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-140006505.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-140006505.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T11:36:31+00:00",
    "headline": "Merck & Co.'s Q4 2025 Earnings: What to Expect",
    "summary": "Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.",
    "url": "https://www.barchart.com/story/news/36901002/merck-co-s-q4-2025-earnings-what-to-expect",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "d8f9ca5c-d146-3ec1-93fa-1f720b92e747",
      "content": {
        "id": "d8f9ca5c-d146-3ec1-93fa-1f720b92e747",
        "contentType": "STORY",
        "title": "Merck & Co.'s Q4 2025 Earnings: What to Expect",
        "description": "",
        "summary": "Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.",
        "pubDate": "2026-01-06T11:36:31Z",
        "displayTime": "2026-01-06T11:36:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/3e1fbe117710034333252a6ae465f0c0",
          "originalWidth": 1254,
          "originalHeight": 836,
          "caption": "Merck & Co Inc HQ -by Sundry Photography via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iL0BHWF7J6pNXhZEIGDG8g--~B/aD04MzY7dz0xMjU0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/3e1fbe117710034333252a6ae465f0c0.cf.webp",
              "width": 1254,
              "height": 836,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xd1jKFXKmcUDM7xRzVyHUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/3e1fbe117710034333252a6ae465f0c0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36901002/merck-co-s-q4-2025-earnings-what-to-expect",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-q4-2025-earnings-113631253.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T17:00:00+00:00",
    "headline": "Allison Worldwide and Stagwell (STGW) Bolster Communications and Healthcare Capabilities in Naming Wendy Lund as Global CEO, Allison and Stagwell's Vice Chair of Health",
    "summary": "NEW YORK CITY, NEW YORK / ACCESS Newswire / January 6, 2026 / Allison Worldwide and Stagwell (NASDAQ:STGW) are turbocharging their global communications capabilities and positioning for growth in healthcare with the appointment of industry veteran ...",
    "url": "https://finance.yahoo.com/news/allison-worldwide-stagwell-stgw-bolster-170000989.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "daec20f2-b3d3-33e1-aaa1-a6f01645b7b8",
      "content": {
        "id": "daec20f2-b3d3-33e1-aaa1-a6f01645b7b8",
        "contentType": "STORY",
        "title": "Allison Worldwide and Stagwell (STGW) Bolster Communications and Healthcare Capabilities in Naming Wendy Lund as Global CEO, Allison and Stagwell's Vice Chair of Health",
        "description": "",
        "summary": "NEW YORK CITY, NEW YORK / ACCESS Newswire / January 6, 2026 / Allison Worldwide and Stagwell (NASDAQ:STGW) are turbocharging their global communications capabilities and positioning for growth in healthcare with the appointment of industry veteran ...",
        "pubDate": "2026-01-06T17:00:00Z",
        "displayTime": "2026-01-06T17:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/c2b75a18ec2d5bc50a6beca927d02f5d",
          "originalWidth": 406,
          "originalHeight": 406,
          "caption": "<![CDATA[NEW YORK CITY, NEW YORK / ACCESS Newswire / January 6, 2026 / Allison Worldwide and Stagwell (NASDAQ:STGW) are turbocharging ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmWRiKLeaB8gGJyqjsksWg--~B/aD00MDY7dz00MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/c2b75a18ec2d5bc50a6beca927d02f5d.cf.webp",
              "width": 406,
              "height": 406,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZIfxXhO4UPoifhsfLcQyKA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/c2b75a18ec2d5bc50a6beca927d02f5d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/allison-worldwide-stagwell-stgw-bolster-170000989.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/allison-worldwide-stagwell-stgw-bolster-170000989.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STGW"
            },
            {
              "symbol": "OGN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "WPP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T23:12:56+00:00",
    "headline": "Assessing Merck (MRK) Valuation As KEYTRUDA Data And New Investment Plans Attract Fresh Investor Attention",
    "summary": "Merck (MRK) is back in focus after a trio of recent developments, including an upcoming J.P. Morgan Healthcare Conference fireside chat, encouraging KEYTRUDA ovarian cancer trial results, and a planned US$1b manufacturing investment in Delaware. See our latest analysis for Merck. Those KEYTRUDA updates, the Cidara tender offer and the big Delaware build out are landing against a backdrop of firming momentum, with Merck’s 30 day share price return at 7.74% and 90 day share price return at...",
    "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-keytruda-231256166.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0956effe-0070-3c7d-87f8-72d4ddcb5bb8",
      "content": {
        "id": "0956effe-0070-3c7d-87f8-72d4ddcb5bb8",
        "contentType": "STORY",
        "title": "Assessing Merck (MRK) Valuation As KEYTRUDA Data And New Investment Plans Attract Fresh Investor Attention",
        "description": "",
        "summary": "Merck (MRK) is back in focus after a trio of recent developments, including an upcoming J.P. Morgan Healthcare Conference fireside chat, encouraging KEYTRUDA ovarian cancer trial results, and a planned US$1b manufacturing investment in Delaware. See our latest analysis for Merck. Those KEYTRUDA updates, the Cidara tender offer and the big Delaware build out are landing against a backdrop of firming momentum, with Merck’s 30 day share price return at 7.74% and 90 day share price return at...",
        "pubDate": "2026-01-06T23:12:56Z",
        "displayTime": "2026-01-06T23:12:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-keytruda-231256166.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-keytruda-231256166.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]